William Blair analyst Sami Corwin maintained a Buy rating on Cabaletta Bio (CABA – Research Report) today. The company’s shares opened today at $12.28.
According to TipRanks, Corwin is a 2-star analyst with an average return of 0.7% and a 45.00% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Legend Biotech, Poseida Therapeutics, and Beam Therapeutics.
Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $32.00.
The company has a one-year high of $26.35 and a one-year low of $9.02. Currently, Cabaletta Bio has an average volume of 1.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cabaletta Bio (CABA) Company Description:
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Read More on CABA:
- Cabaletta Bio Reveals Insights in Updated Corporate Presentation
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Citi reiterates Buy on Cabaletta, says too early to write off CAR-T
- Cabaletta Bio price target raised to $30 from $26 at Citi
